0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

È£½ºÇǽº º´µ¿¿¡ ÀÔ¿øÇÑ ¸»±â¾ÏȯÀÚÀÇ ÅëÁõ°ü¸®

Pain management in terminal cancer patient admitted to hospice ward

È£½ºÇǽº±³À°¿¬±¸¼ÒÁö 1997³â 2±Ç 1È£ p.14 ~ 22
KMID : 0901419970020010014
ÃÖ¼÷°æ ( Choi Suk-Kyung ) - °¡Å縯´ëÇб³ °­³²¼º¸ðº´¿ø È£½ºÇǽºº´µ¿

Abstract

We investigated the characteristics of pain, change of pain degree, change of morphine amount, side effects and other symptoms in 140 patients with terminal cancer who were admitted to the hospice ward of Kangnam St. Mary¡¯s hospital during the period between October 1994 and October 1995. The results were as follows : 1. The mean duration of hospital stay was 30.2 days with range between 1 and 165 days. 76.4% of patients expired in hospice, 15.7% were connected to home hospice care and 5.0% discharged to home immediately before the termination. 2. The most prevalent site of pain was abdomen, regardless of primary site, soft tissue invasion was the most prevalent cause of pain at admission and bone metastasis, carcinomatosis peritonei, hollow viscus invasion followed there after. In patients with fracture and bone metastasis the degree of pain was the highest. 3. At admission, the mean VAS (visual analogue scale) value was 47.7¡¾6.2 and many patients had severe pain, while at the time of the best pain control mean VAS value decreased to 7.0¡¾19.2. At the time of the last hospital interview, mean VAS was staged at 13.2¡¾21 though the pain was increased due to disease aggravation and the occurance other symptoms uncontrolled. In 79 out of 94 patients who were available for pain measurement more than 80% of pain was disappeared 87(73.7%) out of 118 patients who answered too pain questionnaire no pain was achieved and the mean time between the start of treatment and the achievement of no pain was 7 days. 4. The side effects of morphine were sedation, constipation, nausea and vomiting in the decreasing order and there was neither a death associated with side effects nor an addiction to narcotics.
KeyWords
È£½ºÇǽº, ¸»±â¾ÏȯÀÚ, ÅëÁõ
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸